Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

The rising global incidence of breast cancer, driven by lifestyle changes and an aging population, is a key market driver. Technological advancements in diagnostics and treatment, such as molecular ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

Patients with chronic spontaneous urticaria improved early, with benefits lasting through the 52-week follow-up for those who ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

Israeli troops crossed the border for the first time since 2006 in a ground operation targeting Hezbollah. The Israeli military called for evacuations in southern Lebanon. As a Crisis Builds ...

'Trust has become biggest casualty': What Army chief said on LAC standoff with China Army Chief Upendra Dwivedi stated that the situation along the LAC in eastern Ladakh is stable but sensitive ...